Challenges and research progress of the use of mesenchymal stem cells in the treatment of ischemic stroke

Jiang, Jipeng; Wang, Yuting; Liu, Baohu; Chen, Xuyi; Zhang, Sai

doi:10.1016/j.braindev.2018.03.015

Cited by 14 publications

(14 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, our study showed that the inflammation was significantly suppressed clinical trials for ischaemic stroke and other neurological diseases, and there was robust literature confirming the therapeutic effect of stem cell-based treatments for stroke. 50,51 However, direct application of stem cells remains a few issues like potential side effects, including tumourigenicity, immunosuppression, pulmonary embolism 52 and insufficient number of stem cells passing through the blood brain barrier. Due to the small size, exosomes could easily pass the blood brain barrier, confirmed in a murine model.…”

Section: Discussionmentioning

confidence: 99%

Dental pulp stem cell‐derived exosomes alleviate cerebral ischaemia‐reperfusion injury through suppressing inflammatory response

Luo

et al. 2021

Cell Proliferation

View full text Add to dashboard Cite

Objectives The study aimed to determine whether dental pulp stem cell‐derived exosomes (DPSC‐Exos) exert protective effects against cerebral ischaemia‐reperfusion (I/R) injury and explore its underlying mechanism. Materials and Methods Exosomes were isolated from the culture medium of human DPSC. Adult male C57BL/6 mice were subjected to 2 hours transient middle cerebral artery occlusion (tMCAO) injury followed by 2 hours reperfusion, after which singular injection of DPSC‐Exos via tail vein was administrated. Brain oedema, cerebral infarction and neurological impairment were measured on day 7 after exosomes injection. Then, oxygen‐glucose deprivation–reperfusion (OGD/R) induced BV2 cells were studied to analyse the therapeutic effects of DPSC‐Exos on I/R injury in vitro. Protein levels of TLR4, MyD88, NF‐κB p65, HMGB1, IL‐6, IL‐1β and TNF‐α were determined by western blot or enzyme‐linked immunosorbent assay. The cytoplasmic translocation of HMGB1 was detected by immunofluorescence staining. Results DPSC‐Exos alleviated brain oedema, cerebral infarction and neurological impairment in I/R mice. DPSC‐Exos inhibited the I/R‐mediated expression of TLR4, MyD88 and NF‐κB significantly. DPSC‐Exos also reduced the protein expression of IL‐6, IL‐1β and TNF‐α compared with those of the control both in vitro and in vivo. Meanwhile, DPSC‐Exos markedly decreased the HMGB1 cytoplasmic translocation induced by I/R damage. Conclusions DPSC‐Exos can ameliorate I/R‐induced cerebral injury in mice. Its anti‐inflammatory mechanism might be related with the inhibition of the HMGB1/TLR4/MyD88/NF‐κB pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Dental pulp stem cell‐derived exosomes alleviate cerebral ischaemia‐reperfusion injury through suppressing inflammatory response

Luo

et al. 2021

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…121 For their ability to home to damaged tissue and instigate repair, MSCs are also being investigated as treatment for pulmonary fibrosis, 107 radiation-induced aortic injury, 122 and ischemic stroke. 123 Additionally, MSCs are able to undergo diapedesis from blood into tissues, allowing for the potential of intravascular MSC treatment. 124 Due to their lack of cell-surface Major histocompatibility complex and co-stimulatory molecule expression, 125 allogeneic MSCs have low immunogenicity and can be used therapeutically without immunosuppression.…”

Section: Endog Enous Org An -S Pecific S Tem Cell Smentioning

confidence: 99%

Challenges, highlights, and opportunities in cellular transplantation: A white paper of the current landscape

Parsons

Baquerizo

Kirchner

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

Although cellular transplantation remains a relatively small field compared to solid organ transplantation, the prospects for advancement in basic science and clinical care remain bountiful. In this review, notable historical events and the current landscape of the field of cellular transplantation are reviewed with an emphasis on islets (allo-and xeno-), hepatocytes (including bioartificial liver), adoptive regulatory immunotherapy, and stem cells (SCs, specifically endogenous organ-specific and mesenchymal). Also, the nascent but rapidly evolving field of three-dimensional bioprinting is highlighted, including its major processing steps and latest achievements. To reach its full potential where cellular transplants are a more viable alternative than solid organ transplants, fundamental change in how the field is regulated and advanced is needed. Greater public and private investment in the development of cellular transplantation is required. Furthermore, consistent with the call of multiple national transplant societies for allo-islet transplants, the oversight of cellular transplants should mirror that of solid organ transplants and not be classified under the unsustainable, outdated model | 3227 AJT PARSONS et Al.

show abstract

“…Bone marrow-derived mesenchymal autologous stem cells (BMMSCs) were the subject of many clinical and preclinical studies on ischemic stroke as they have been shown to endorse synaptogenesis and brain tissue regeneration and to improve motor and sensory functions, concomitantly having immunomodulatory effects on the inflammatory mediated immune response following cerebral ischemia. Autologous BMMSCs have the advantage of being safe from triggering autoimmune reactions, which may be present in the use of non-autologous cell therapies, and of having been proven safe and feasible in human clinical trials for stroke [119,120,121,122]. Induced pluripotent SCs, derived from programming fibroblasts and mononuclear cells from the peripheral blood, have been successfully used in stroke patients.…”

Section: Therapeutic Stem Cells After Ischemic Stroke: Current Statusmentioning

confidence: 99%

Modern Concepts in Regenerative Therapy for Ischemic Stroke: From Stem Cells for Promoting Angiogenesis to 3D-Bioprinted Scaffolds Customized via Carotid Shear Stress Analysis

Benedek¹,

Cernica²,

Mester³

et al. 2019

IJMS

View full text Add to dashboard Cite

Ischemic stroke is associated with a tremendous economic and societal burden, and only a few therapies are currently available for the treatment of this devastating disease. The main therapeutic approaches used nowadays for the treatment of ischemic brain injury aim to achieve reperfusion, neuroprotection and neurorecovery. Therapeutic angiogenesis also seems to represent a promising tool to improve the prognosis of cerebral ischemia. This review aims to present the modern concepts and the current status of regenerative therapy for ischemic stroke and discuss the main results of major clinical trials addressing the effectiveness of stem cell therapy for achieving neuroregeneration in ischemic stroke. At the same time, as a glimpse into the future, this article describes modern concepts for stroke prevention, such as the implantation of bioprinted scaffolds seeded with stem cells, whose 3D geometry is customized according to carotid shear stress.

show abstract

Challenges and research progress of the use of mesenchymal stem cells in the treatment of ischemic stroke

Cited by 14 publications

References 118 publications

Dental pulp stem cell‐derived exosomes alleviate cerebral ischaemia‐reperfusion injury through suppressing inflammatory response

Dental pulp stem cell‐derived exosomes alleviate cerebral ischaemia‐reperfusion injury through suppressing inflammatory response

Challenges, highlights, and opportunities in cellular transplantation: A white paper of the current landscape

Modern Concepts in Regenerative Therapy for Ischemic Stroke: From Stem Cells for Promoting Angiogenesis to 3D-Bioprinted Scaffolds Customized via Carotid Shear Stress Analysis

Contact Info

Product

Resources

About